MWNA
DYN icon

Marshall Wace North America’s Dyne Therapeutics DYN Stock Holding History

Marshall Wace North America’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$5.31M Sell
327,227
-2,269
-0.7% -$40.2K 0.02% 490
2021
Q2 		$6.93M Buy
+329,496
New +$6.2M 0.03% 458
2020
Q4 		– Sell
-42,623
Closed -$861K – 1373
2020
Q3 		$861K Buy
+42,623
New +$935K 0.01% 840

Other funds holding DYN

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Marshall Wace North America's DYN Position: Q3 2021 in Review

Marshall Wace North America reduced its Dyne Therapeutics (DYN) stake by 0.69% in Q3 2021, selling an estimated $40.2K and leaving 327,227 shares worth $5.31M. The position accounts for 0.02% of the portfolio, ranked #490.

Marshall Wace North America first reported a position in DYN in Q3 2020 and has held it in 3 quarters since. The position peaked at $6.93M in Q2 2021. 83 funds tracked by Wall St. Rank hold DYN as of Q3 2021.

  • Marshall Wace North America held 327,227 shares of Dyne Therapeutics worth $5.31M as of Q3 2021.
  • Marshall Wace North America sold 2,269 Dyne Therapeutics shares in Q3 2021, an estimated $40.2K.
  • Dyne Therapeutics made up 0.02% of Marshall Wace North America's portfolio in Q3 2021, its #490 holding.
  • Marshall Wace North America first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 3 quarters since.
  • Marshall Wace North America's Dyne Therapeutics position peaked at $6.93M in Q2 2021.
  • 83 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.